FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2033580963> ?p ?o ?g. }

• W2033580963 endingPage "1743" @default.
• W2033580963 startingPage "1735" @default.
• W2033580963 abstract "BackgroundMast cells play a critical role in inflammatory skin diseases through releasing proinflammatory mediators; however, few therapies directly target these cells. In 1878, the use of topical thymol, a now recognized potent agonist for transient receptor potential channels, was first described to treat eczema and psoriasis.ObjectiveWe sought to determine the mechanisms through which thymol can alter skin inflammation.MethodsWe examined the effect of topical thymol on IgE-dependent responses using a mast cell–dependent passive cutaneous anaphylaxis (PCA) model, as well as in vitro–cultured mast cells.ResultsThymol dose-dependently inhibited PCA when administered topically 24 hours before antigen challenge but provoked an ear-swelling response directly on application. This direct effect was associated with local mast cell degranulation and was absent in histamine-deficient mice. However, unlike with PCA responses, there was no late-phase swelling. In vitro thymol directly triggered calcium flux in mast cells through transient receptor potential channel activation, along with degranulation and cytokine transcription. However, no cytokine protein was produced. Instead, thymol induced a significant increase in apoptotic cell death that was seen both in vitro and in vivo.ConclusionsWe propose that the efficacy of thymol in reducing IgE-dependent responses is through promotion of activation-induced apoptotic cell death of mast cells and that this likely explains the clinical benefits observed in early clinical reports. Mast cells play a critical role in inflammatory skin diseases through releasing proinflammatory mediators; however, few therapies directly target these cells. In 1878, the use of topical thymol, a now recognized potent agonist for transient receptor potential channels, was first described to treat eczema and psoriasis. We sought to determine the mechanisms through which thymol can alter skin inflammation. We examined the effect of topical thymol on IgE-dependent responses using a mast cell–dependent passive cutaneous anaphylaxis (PCA) model, as well as in vitro–cultured mast cells. Thymol dose-dependently inhibited PCA when administered topically 24 hours before antigen challenge but provoked an ear-swelling response directly on application. This direct effect was associated with local mast cell degranulation and was absent in histamine-deficient mice. However, unlike with PCA responses, there was no late-phase swelling. In vitro thymol directly triggered calcium flux in mast cells through transient receptor potential channel activation, along with degranulation and cytokine transcription. However, no cytokine protein was produced. Instead, thymol induced a significant increase in apoptotic cell death that was seen both in vitro and in vivo. We propose that the efficacy of thymol in reducing IgE-dependent responses is through promotion of activation-induced apoptotic cell death of mast cells and that this likely explains the clinical benefits observed in early clinical reports." @default.
• W2033580963 created "2016-06-24" @default.
• W2033580963 creator A5006817794 @default.
• W2033580963 creator A5034360741 @default.
• W2033580963 creator A5053743795 @default.
• W2033580963 date "2014-06-01" @default.
• W2033580963 modified "2023-09-29" @default.
• W2033580963 title "IgE-mediated mast cell responses are inhibited by thymol-mediated, activation-induced cell death in skin inflammation" @default.
• W2033580963 cites W1487546264 @default.
• W2033580963 cites W1560997848 @default.
• W2033580963 cites W1569530493 @default.
• W2033580963 cites W1598488986 @default.
• W2033580963 cites W1820139896 @default.
• W2033580963 cites W1912587416 @default.
• W2033580963 cites W1967584575 @default.
• W2033580963 cites W1968131925 @default.
• W2033580963 cites W1968563039 @default.
• W2033580963 cites W1979082679 @default.
• W2033580963 cites W1988860455 @default.
• W2033580963 cites W1991396423 @default.
• W2033580963 cites W1991952578 @default.
• W2033580963 cites W1993037363 @default.
• W2033580963 cites W2008235383 @default.
• W2033580963 cites W2012585412 @default.
• W2033580963 cites W2016735587 @default.
• W2033580963 cites W2021085683 @default.
• W2033580963 cites W2023224340 @default.
• W2033580963 cites W2028851206 @default.
• W2033580963 cites W2035876173 @default.
• W2033580963 cites W2036471639 @default.
• W2033580963 cites W2036567710 @default.
• W2033580963 cites W2042102056 @default.
• W2033580963 cites W2045454662 @default.
• W2033580963 cites W2053695562 @default.
• W2033580963 cites W2057069458 @default.
• W2033580963 cites W2058894046 @default.
• W2033580963 cites W2063299731 @default.
• W2033580963 cites W2064180188 @default.
• W2033580963 cites W2068619626 @default.
• W2033580963 cites W2077747679 @default.
• W2033580963 cites W2091639781 @default.
• W2033580963 cites W2096773815 @default.
• W2033580963 cites W2098574165 @default.
• W2033580963 cites W2099660723 @default.
• W2033580963 cites W2102873430 @default.
• W2033580963 cites W2110775739 @default.
• W2033580963 cites W2125715317 @default.
• W2033580963 cites W2127138632 @default.
• W2033580963 cites W2130614990 @default.
• W2033580963 cites W2138002999 @default.
• W2033580963 cites W2143036393 @default.
• W2033580963 cites W2149826773 @default.
• W2033580963 cites W2151388489 @default.
• W2033580963 cites W2151720661 @default.
• W2033580963 cites W2154750376 @default.
• W2033580963 cites W2155519371 @default.
• W2033580963 cites W2158921004 @default.
• W2033580963 cites W2162266779 @default.
• W2033580963 cites W2162936113 @default.
• W2033580963 cites W2164150729 @default.
• W2033580963 cites W2169100849 @default.
• W2033580963 cites W2278089869 @default.
• W2033580963 cites W2314713895 @default.
• W2033580963 cites W2316997614 @default.
• W2033580963 cites W2733686 @default.
• W2033580963 cites W2925184086 @default.
• W2033580963 cites W4230690546 @default.
• W2033580963 cites W4246622814 @default.
• W2033580963 cites W4255643006 @default.
• W2033580963 doi "https://doi.org/10.1016/j.jaci.2013.12.024" @default.
• W2033580963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4040322" @default.
• W2033580963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24486068" @default.
• W2033580963 hasPublicationYear "2014" @default.
• W2033580963 type Work @default.
• W2033580963 sameAs 2033580963 @default.
• W2033580963 citedByCount "34" @default.
• W2033580963 countsByYear W20335809632014 @default.
• W2033580963 countsByYear W20335809632015 @default.
• W2033580963 countsByYear W20335809632016 @default.
• W2033580963 countsByYear W20335809632017 @default.
• W2033580963 countsByYear W20335809632018 @default.
• W2033580963 countsByYear W20335809632019 @default.
• W2033580963 countsByYear W20335809632020 @default.
• W2033580963 countsByYear W20335809632021 @default.
• W2033580963 countsByYear W20335809632022 @default.
• W2033580963 countsByYear W20335809632023 @default.
• W2033580963 crossrefType "journal-article" @default.
• W2033580963 hasAuthorship W2033580963A5006817794 @default.
• W2033580963 hasAuthorship W2033580963A5034360741 @default.
• W2033580963 hasAuthorship W2033580963A5053743795 @default.
• W2033580963 hasBestOaLocation W20335809631 @default.
• W2033580963 hasConcept C1122143 @default.
• W2033580963 hasConcept C141105273 @default.
• W2033580963 hasConcept C159654299 @default.
• W2033580963 hasConcept C164027704 @default.
• W2033580963 hasConcept C170493617 @default.
• W2033580963 hasConcept C185592680 @default.
• W2033580963 hasConcept C203014093 @default.

• next